Product
Relatlimab
Aliases
Anti-LAG-3 (Anti-Lymphocyte Activation Gene-3), BMS986016, BMS-986016, BMS-986016-01, Immunoglobulin G4, Anti-(human Lymphocyte Activation Gene-3 Protein) (Human Heavy Chain), Disulfide with Human Light Chain, Dimer (1 other aliases)
35 clinical trials
81 indications
Indication
CancerIndication
Hepatocellular CarcinomaIndication
Liver cancerIndication
Liver CancerIndication
AdultIndication
Neoplasms by SiteIndication
cancerIndication
HepatocellularIndication
lymphomaIndication
Non-HodgkinIndication
Large B-CellIndication
DiffuseIndication
FollicularIndication
Advanced CancerIndication
Stomach CancerIndication
MelanomaIndication
Lung CancerIndication
Recurrent Non-small Cell Lung CancerIndication
Metastatic Non-small Cell Lung CancerIndication
MSI-High TumorsIndication
Gastroesophageal CancerIndication
immune checkpoint inhibitionIndication
Mucosal melanomaIndication
Ocular melanomaIndication
Acral Lentiginous MelanomaIndication
Cutaneous MelanomaIndication
Uveal MelanomaIndication
Uveal Melanoma (Stage IIIC, AJCC v7)Indication
Stage IV Cutaneous MelanomaIndication
Urologic NeoplasmsIndication
Urogenital NeoplasmsIndication
Female Urogenital DiseasesIndication
Urogenital DiseasesIndication
Bladder DiseasesIndication
Male Urogenital DiseasesIndication
Bladder CancerIndication
Antineoplastics ToxicityIndication
Bladder Urothelial CarcinomaIndication
Bladder Urothelial Carcinoma AJCC v7Indication
Colorectal AdenocarcinomasIndication
Colorectal AdenocarcinomaIndication
LymphomaIndication
Malignant NeoplasmIndication
Malignant Solid NeoplasmIndication
Multiple MyelomaIndication
Head and Neck Squamous Cell CarcinomaIndication
Renal Pelvis Urothelial CarcinomaIndication
Ureter Urothelial CarcinomaIndication
Urethral Urothelial CarcinomaIndication
Urothelial CarcinomaIndication
Metastatic Bladder Urothelial CarcinomaIndication
Metastatic Urothelial CarcinomaIndication
Recurrent Ureter Urothelial CarcinomaIndication
Recurrent Urethral Urothelial CarcinomaIndication
Recurrent Urothelial CarcinomaIndication
Bladder Cancer Stage III AJCC v8Indication
Hodgkin lymphomaIndication
Stage III Renal Pelvis CancerIndication
Ureter Cancer AJCC v8Indication
Urethral Cancer AJCC v8Indication
Bladder Cancer AJCC v8Indication
Stage IV Bladder CancerIndication
Stage IV Renal Pelvis CancerIndication
Stage IV Ureter Cancer AJCC v8Indication
Urethral CancerIndication
Bladder Cancer, Stage IVA (AJCC v8)Indication
Unresectable Ureter Urothelial CarcinomaIndication
Unresectable Urothelial CarcinomaIndication
CarcinomaIndication
Renal Medullary CarcinomaIndication
Esophageal cancerIndication
Gastric Esophageal CancerIndication
Basal Cell CarcinomaIndication
Non-Small Cell Lung Cancer Stage IIIndication
NSCLCIndication
Stage IIIAIndication
Stage IIndication
ChordomaIndication
Metastatic MelanomaClinical trial
A Phase 1 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) in Combination With Nivolumab (Anti-PD-1 Monoclonal Antibody) in Chinese Participants With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2024-01-18
Clinical trial
A Phase 2, Randomized, Open-label Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Hepatocellular Carcinoma Who Are Naive to IO Therapy But Progressed on Tyrosine Kinase Inhibitors (RELATIVITY-073)Status: Active (not recruiting), Estimated PCD: 2023-08-31
Clinical trial
A Phase 1 Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-07-05
Clinical trial
A Phase I/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination With Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2024-09-10
Clinical trial
A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular CarcinomaStatus: Recruiting, Estimated PCD: 2024-06-04
Clinical trial
An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM)Status: Completed, Estimated PCD: 2023-02-15
Clinical trial
Pan-Tumor Study for Long-term Treatment of Cancer Patients Who Have Participated in BMS Sponsored Trials Investigating Nivolumab and Other Cancer TherapiesStatus: Recruiting, Estimated PCD: 2029-08-25
Clinical trial
A Phase 1/2 Study of Relatlimab (Anti-LAG-3 Monoclonal Antibody) Administered in Combination With Both Nivolumab (Anti-PD-1 Monoclonal Antibody) and BMS-986205 (IDO1 Inhibitor) or in Combination With Both Nivolumab and Ipilimumab (Anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant TumorsStatus: Active (not recruiting), Estimated PCD: 2024-04-22
Clinical trial
A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)Status: Completed, Estimated PCD: 2021-11-23
Clinical trial
ADaptiVe Biomarker Trial That InformS Evolution of TherapyStatus: Completed, Estimated PCD: 2021-03-31
Clinical trial
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)Status: Completed, Estimated PCD: 2022-05-11
Clinical trial
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)Status: Active (not recruiting), Estimated PCD: 2024-05-28
Clinical trial
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination With Ipilimumab or Ipilimumab Alone in Participants With Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 TherapyStatus: Completed, Estimated PCD: 2023-07-26
Clinical trial
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable MelanomaStatus: Active (not recruiting), Estimated PCD: 2021-01-25
Clinical trial
Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects With Virus-Positive and Virus-Negative Solid TumorsStatus: Completed, Estimated PCD: 2021-03-19
Clinical trial
Phase 2 Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 InhibitorStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
REACTION (Radiation Enhanced Assessment of Combination Therapies in Immuno-ONcology) - Nivolumab or Nivolumab in Combination With Other Immuno-oncology (IO) Agents After Targeted Systemic Radiation in Patients With Advanced Esophagogastric CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Neoadjuvant and Adjuvant Checkpoint Blockade in Patients With Clinical Stage III or Oligometastatic Stage IV MelanomaStatus: Completed, Estimated PCD: 2023-01-26
Clinical trial
A Phase 2 Trial in Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without RelatlimabStatus: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcerStatus: Recruiting, Estimated PCD: 2026-04-11
Clinical trial
Phase A Phase 2 Study Evaluating Response and Biomarkers in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Treated With Nivolumab in Combination With RelatlimabStatus: Active (not recruiting), Estimated PCD: 2024-02-23
Clinical trial
MATCH Treatment Subprotocol Z1M: Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients With LAG-3+ Tumors With Mismatch Repair Deficiency (MMR-d) After Progression on Anti-PD-1/PD-L1 TherapyStatus: Withdrawn, Estimated PCD: 2023-01-17
Clinical trial
A Phase II Neoadjuvant Study of the Safety and Tolerability of Anti-PD1 (Nivolumab) Administered Alone or in Combination With Anti-LAG3 (Relatlimab) or Anti-CTLA4 (Ipilimumab) in Resectable Head and Neck CancerStatus: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
A Phase II Clinical Trial to Investigate ARID1A Mutation and CXCL13 Expression in the Pre-Treatment Tumor Samples as a Combinatorial Predictive Biomarker for Immune Checkpoint Therapy in Metastatic Urothelial CancerStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin LymphomaStatus: Recruiting, Estimated PCD: 2028-07-05
Clinical trial
Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal MedullaStatus: Recruiting, Estimated PCD: 2027-07-16
Clinical trial
Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction CancerStatus: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell CarcinomaStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase 2 Study of Nivolumab + BMS-986016 (Relatlimab) in Patients With Metastatic Uveal MelanomaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Feasibility and Efficacy of Perioperative Nivolumab With or Without Relatlimab for Patients With Potentially Resectable Hepatocellular Carcinoma (HCC)Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase II Study of Anti-PD1 Monoclonal Antibody (Nivolumab, BMS-936558) Administered in Combination With Anti-LAG3 Monoclonal Antibody (Relatlimab, BMS-986016) in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic SettingStatus: Active (not recruiting), Estimated PCD: 2027-07-31
Clinical trial
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain MetastasesStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Clinical trial
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients: Defining Optimal Combinations and Determinants of Immunological ResponseStatus: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Signal Finding Phase 2 Study of Nivolumab (Anti-PD-1; BMS-936558; ONO-4538) and Relatlimab (Anti-LAG-3 Monoclonal Antibody; BMS-986016) in Patients With Advanced ChordomaStatus: Completed, Estimated PCD: 2023-09-28
Clinical trial
A Phase II Study of PD-1 Blockade With or Without LAG-3 Inhibition in Combination With Infliximab for the Treatment of Metastatic Melanoma and Prevention of Adverse EventsStatus: Recruiting, Estimated PCD: 2025-06-30